Clinical trials: Moderate Cognitive Impairment
Traumatic Brain Injury, Cognitive Impairment
Strategy Based Technique to Enhance Memory (STEM) for Improving New Learning and Memory (NLM) in Moderate to Severe TBI
The purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with a Traumatic Brian Injury (TBI).
- Trial name
- STEM (NCT04054596)
- Testing
- SME
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Kessler Foundation
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Cognitive Impairment
Cost-utility Analysis of the Use of the Paro Robotic Seal by Elderly Patients With Moderate or Severe Cognitive Disorders in Institutions: a Randomised Study.
Many residents from establishments for dependent elderly people (EHPAD) have memory disorders with behavioural problems such as agitation, aggression and anxiety, which make it difficult to assist them on a daily basis.
- Trial name
- PEPINO (NCT04941222)
- Testing
- With robotic seal "PARO"
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Alzheimer's Disease
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00454870
- Testing
- MEM 3454
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memory Pharmaceuticals
Mild Cognitive Impairment, Mild Dementia
Gait, cOgnitiOn & Decline (GOOD)
The main objective of the GOOD initiative was to determine which spatio-temporal gait parameters and/or combination(s) of spatio-temporal gait parameters best differentiate between cognitively healthy individuals (CHI), patients…
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Healthy
- Trial name
- NCT02350270
- Testing
- gait and cognitive testing
- Where
- France
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Alzheimer Disease
Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease
In the study at hand, six patients with light to moderate Alzheimer's disease will be enrolled and implanted with bilateral electrodes in the nucleus basalis Meynert.
- Trial name
- MeynD-DBS (NCT01094145)
- Testing
- Deep brain stimulation
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- University of Cologne
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease.
- Trial name
- NCT05466422
- Testing
- MK-2214
- Where
- 12 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients with Alzheimer's disease.
- Trial name
- NCT00035204
- Testing
- galantamine
- Volunteers
- 63 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dementia, Cognitive Impairment
Caring for Persons With Dementia and Their Caregivers in the Community
The study consists of two phases - i) a comprehensive assessment of biopsychosocial needs among cognitively impaired persons and their family caregivers residing in the Whampoa residential estate in Singapore ; ii) a…
- Trial name
- NCT04479033
- Testing
- Multidisciplinary collaborative model of community care management
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Duke-NUS Graduate Medical School
Mild Cognitive Impairment (MCI), Moderate Cognitive Impairment
Comparative Effects of Integrated Versus Sequential Approaches to Dual-Task Training in Elderly With Mild to Moderate Cognitive Impairment
Mild and Moderate cognitive impairment is a condition characterized by a noticeable decline in cognitive abilities, including memory and thinking skills, which is greater than expected for an individual's age but does not…
- Trial name
- nill (NCT07775079)
- Testing
- Integrated Dual-Task Training, Sequential Dual-Task Training
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Shifa Tameer-e-Millat University
Alzheimer's Disease
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better.
- Trial name
- NCT00876863
- Testing
- CERE-110: Adeno-Associated Virus injection Surgery
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sangamo Therapeutics
Moderate Acute Malnutrition
Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old
The aim of this open-label randomized controlled trial conducted in four African countries (Madagascar, Niger, Central African Republic and Senegal) is to compare three strategies of renutrition for moderate acute malnutrition…
- Trial name
- MALINEA (NCT03474276)
- Testing
- Azythromycin, Inuline and fructo-oligosaccharides, Albendazole
- Where
- 4 sites in Central African Republic, Madagascar and 2 more
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Mild, Moderate, or Severe Alzheimer's Disease
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
- Trial name
- NCT06745583
- Testing
- EI-1071 tablet, oral
- Where
- 2 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Elixiron Immunotherapeutics Inc.
Alzheimer Disease, Mild Cognitive Impairment
A Study of NTRX-07 in Participants With Alzheimer's Disease
1. Study Overview NeuroTherapia Inc. is conducting a clinical study to explore the safety and effects of a new drug called NTRX- 07.
- Trial name
- SPPN-AD (NCT07058688)
- Testing
- NTRX-07
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 48 people
- Sponsor
- NeuroTherapia, Inc.
Brain Injury, Chronic
Treatment of Traumatic Brain Injury With Hyperbaric Oxygen Therapy
The purpose of this study is to determine if hyperbaric oxygen therapy (HBOT) improves the cognitive function of OIF/OEF individuals who have chronic mild to moderate traumatic brain injury (TBI).
- Trial name
- NCT00810615
- Testing
- Hyperbaric oxygen @ 2.4 ATA
- Volunteers
- 50 people
- Sponsor
- San Antonio Military Medical Center
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Cardiovascular Diseases, Inflammation
Dietary Intake of Alpha-linolenic Acid in Elderly
The purpose of this study is to evaluate the antiatherogenic and anti-inflammatory potential of an adequate intake of alpha-linolenic acid in elderly.
- Conditions
- Cardiovascular Diseases, Inflammation, Metabolism Disorder, Lipid
- Trial name
- NCT03025620
- Testing
- Rapeseed oil, Sunflower oil
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Older Adults, Cognitive Impairment
Intranasal Dexmedetomidine-esketamine on Sleep and Cognition in Older Adults With Mild-to-moderate Cognitive Impairment
Patients with cognitive decline are frequently comorbid with sleep disorders which may in turn aggravate cognitive decline. Sedative dose dexmedetomidine improved sleep quality but incresed bradycardia and hypotension; low dose…
- Conditions
- Older Adults, Cognitive Impairment, Sleep Disorders, Dexmedetomidine
- Trial name
- NCT07610343
- Testing
- Dexmedetomidine-esketamine combination
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital